Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
74
PBYI Quote, Financials, Valuation and Earnings
Last price:
$6.43
Seasonality move
:
0.26%
Day range:
$6.55 - $7.21
52-week range:
$2.58 - $7.21
Dividend yield:
0%
P/E ratio:
9.26x
P/S ratio:
1.62x
P/B ratio:
3.00x
Volume:
767.1K
Avg. volume:
402.4K
1-year change:
132.54%
Market cap:
$345.7M
Revenue:
$230.5M
EPS (TTM):
$0.74
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
|
$68.6M | $0.23 | 16.12% | -41.13% | $3.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$289.1M | $0.14 | 16.55% | 16.61% | $30.84 |
|
CRMD
CorMedix, Inc.
|
$126.7M | $0.80 | 195.3% | 90.44% | $15.57 |
|
NEPH
Nephros, Inc.
|
$4.5M | $0.01 | 15.01% | -69.79% | $6.50 |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -- | -- | -- | $6.67 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
|
$6.86 | $3.50 | $345.7M | 9.26x | $0.00 | 0% | 1.62x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.51 | $30.84 | $4.7B | 17.70x | $0.00 | 0% | 4.42x |
|
CRMD
CorMedix, Inc.
|
$7.44 | $15.57 | $586.2M | 3.62x | $0.00 | 0% | 2.51x |
|
NEPH
Nephros, Inc.
|
$4.66 | $6.50 | $49.5M | 33.74x | $0.00 | 0% | 2.80x |
|
RLMD
Relmada Therapeutics, Inc.
|
$3.96 | $6.67 | $290.4M | -- | $0.00 | 0% | -- |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.10 | $13.63 | $478.7M | -- | $0.00 | 0% | 2.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.825 | 1.52% | 2.70x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
NEPH
Nephros, Inc.
|
10.34% | 3.066 | 2.3% | 3.17x |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | 5.792 | -- | 2.68x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
NEPH
Nephros, Inc.
|
$2.9M | $314K | 14.16% | 16.22% | 6.59% | $99K |
|
RLMD
Relmada Therapeutics, Inc.
|
-- | -$10.3M | -214.4% | -214.4% | -- | -$6.7M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Puma Biotechnology, Inc. vs. Competitors
-
Which has Higher Returns PBYI or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 25.76%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About PBYI or ACAD?
Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -48.98%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $30.84 which suggests that it could grow by 12.11%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBYIPuma Biotechnology, Inc.0 1 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is PBYI or ACAD More Risky?
Puma Biotechnology, Inc. has a beta of 1.187, which suggesting that the stock is 18.747% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.083%.
-
Which is a Better Dividend Stock PBYI or ACAD?
Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBYI or ACAD?
Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Puma Biotechnology, Inc.'s net income of $8.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.26x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.62x versus 4.42x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBYIPuma Biotechnology, Inc.1.62x 9.26x $54.5M $8.8M ACADACADIA Pharmaceuticals, Inc.4.42x 17.70x $278.6M $71.8M
-
Which has Higher Returns PBYI or CRMD?
CorMedix, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 49.9%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About PBYI or CRMD?
Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -48.98%. On the other hand CorMedix, Inc. has an analysts' consensus of $15.57 which suggests that it could grow by 109.29%. Given that CorMedix, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe CorMedix, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBYIPuma Biotechnology, Inc.0 1 0 CRMDCorMedix, Inc.4 0 0 -
Is PBYI or CRMD More Risky?
Puma Biotechnology, Inc. has a beta of 1.187, which suggesting that the stock is 18.747% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock PBYI or CRMD?
Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBYI or CRMD?
Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Puma Biotechnology, Inc.'s net income of $8.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.26x while CorMedix, Inc.'s PE ratio is 3.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.62x versus 2.51x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBYIPuma Biotechnology, Inc.1.62x 9.26x $54.5M $8.8M CRMDCorMedix, Inc.2.51x 3.62x $104.3M $108.6M
-
Which has Higher Returns PBYI or NEPH?
Nephros, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of 7.07%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Nephros, Inc.'s return on equity of 16.22%.
Company Gross Margin Earnings Per Share Invested Capital PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M NEPHNephros, Inc.60.47% $0.03 $11.2M -
What do Analysts Say About PBYI or NEPH?
Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -48.98%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 39.49%. Given that Nephros, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Nephros, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBYIPuma Biotechnology, Inc.0 1 0 NEPHNephros, Inc.1 0 0 -
Is PBYI or NEPH More Risky?
Puma Biotechnology, Inc. has a beta of 1.187, which suggesting that the stock is 18.747% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.407, suggesting its more volatile than the S&P 500 by 40.722%.
-
Which is a Better Dividend Stock PBYI or NEPH?
Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBYI or NEPH?
Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Nephros, Inc.'s net income of $337K. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.26x while Nephros, Inc.'s PE ratio is 33.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.62x versus 2.80x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBYIPuma Biotechnology, Inc.1.62x 9.26x $54.5M $8.8M NEPHNephros, Inc.2.80x 33.74x $4.8M $337K
-
Which has Higher Returns PBYI or RLMD?
Relmada Therapeutics, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of --. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Relmada Therapeutics, Inc.'s return on equity of -214.4%.
Company Gross Margin Earnings Per Share Invested Capital PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M RLMDRelmada Therapeutics, Inc.-- -$0.30 $9.5M -
What do Analysts Say About PBYI or RLMD?
Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -48.98%. On the other hand Relmada Therapeutics, Inc. has an analysts' consensus of $6.67 which suggests that it could grow by 68.35%. Given that Relmada Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Relmada Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBYIPuma Biotechnology, Inc.0 1 0 RLMDRelmada Therapeutics, Inc.2 1 0 -
Is PBYI or RLMD More Risky?
Puma Biotechnology, Inc. has a beta of 1.187, which suggesting that the stock is 18.747% more volatile than S&P 500. In comparison Relmada Therapeutics, Inc. has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.834%.
-
Which is a Better Dividend Stock PBYI or RLMD?
Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Relmada Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBYI or RLMD?
Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are larger than Relmada Therapeutics, Inc. quarterly revenues of --. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Relmada Therapeutics, Inc.'s net income of -$10.1M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.26x while Relmada Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.62x versus -- for Relmada Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBYIPuma Biotechnology, Inc.1.62x 9.26x $54.5M $8.8M RLMDRelmada Therapeutics, Inc.-- -- -- -$10.1M
-
Which has Higher Returns PBYI or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 16.24% compared to Puma Biotechnology, Inc.'s net margin of -40.15%. Puma Biotechnology, Inc.'s return on equity of 38.49% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About PBYI or VNDA?
Puma Biotechnology, Inc. has a consensus price target of $3.50, signalling downside risk potential of -48.98%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 68.21%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PBYIPuma Biotechnology, Inc.0 1 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is PBYI or VNDA More Risky?
Puma Biotechnology, Inc. has a beta of 1.187, which suggesting that the stock is 18.747% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock PBYI or VNDA?
Puma Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Puma Biotechnology, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PBYI or VNDA?
Puma Biotechnology, Inc. quarterly revenues are $54.5M, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Puma Biotechnology, Inc.'s net income of $8.8M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Puma Biotechnology, Inc.'s price-to-earnings ratio is 9.26x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Puma Biotechnology, Inc. is 1.62x versus 2.24x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PBYIPuma Biotechnology, Inc.1.62x 9.26x $54.5M $8.8M VNDAVanda Pharmaceuticals, Inc.2.24x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.01% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is down 12.81% over the past day.
Buy
80
MTRN alert for Jan 23
Materion Corp. [MTRN] is down 9.13% over the past day.
